Remove Pharmaceuticals Remove Pharmacy Remove Webinar
article thumbnail

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription. Click here to see the original post from December 2023.

article thumbnail

Drug Wholesalers and Brand-Name Drug Prices: Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s

Drug Channels

Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PBMs and the Battle Over Patient Support Funds:Accumulators, Maximizers, and Alternative Funding (NEW Live Video Webinar)

Drug Channels

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding This event will be broadcast live on Friday, June 23, 2023, from 12:00 p.m. Pharmacies and Pharmacy Benefit Managers.

article thumbnail

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (NEW Live Video Webinar)

Drug Channels

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. Pharmacies and Pharmacy Benefit Managers.

article thumbnail

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Drug Channels

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Today, I examine these PBM-owned GPOs and then speculate on five plausible explanations for their existence. to 1:30 p.m.

article thumbnail

Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis (rerun)

Drug Channels

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The 340B contract pharmacy market shows little sign of slowing down. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J.

article thumbnail

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

Drug Channels

As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S. healthcare spending. healthcare spending growth. healthcare spending growth. to 1:30 p.m.